Barrington Research Cuts Earnings Estimates for Haemonetics

Haemonetics Corporation (NYSE:HAE) – Investment analysts at Barrington Research decreased their Q3 2026 EPS estimates for Haemonetics in a research note issued to investors on Friday, November 7th. Barrington Research analyst M. Petusky now anticipates that the medical instruments supplier will earn $1.27 per share for the quarter, down from their prior estimate of $1.30. Barrington Research currently has a “Outperform” rating and a $90.00 price objective on the stock. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share. Barrington Research also issued estimates for Haemonetics’ Q4 2026 earnings at $1.29 EPS, FY2026 earnings at $4.93 EPS, Q1 2027 earnings at $1.21 EPS, Q2 2027 earnings at $1.43 EPS, Q3 2027 earnings at $1.40 EPS, Q4 2027 earnings at $1.42 EPS, FY2027 earnings at $5.45 EPS and FY2028 earnings at $6.00 EPS.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.15. The firm had revenue of $327.32 million during the quarter, compared to analyst estimates of $311.61 million. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.Haemonetics’s revenue for the quarter was down 5.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.12 EPS. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS.

HAE has been the topic of a number of other research reports. Citigroup decreased their target price on Haemonetics from $78.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday, October 7th. Weiss Ratings downgraded shares of Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Saturday, October 25th. Needham & Company LLC boosted their target price on shares of Haemonetics from $68.00 to $78.00 and gave the stock a “buy” rating in a research note on Friday. BTIG Research upped their price target on shares of Haemonetics from $85.00 to $88.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $62.00 price objective (down from $85.00) on shares of Haemonetics in a report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Haemonetics presently has a consensus rating of “Moderate Buy” and an average target price of $78.50.

Haemonetics Stock Up 2.4%

Shares of HAE opened at $68.70 on Monday. The firm has a market cap of $3.31 billion, a P/E ratio of 21.01, a PEG ratio of 0.91 and a beta of 0.43. Haemonetics has a 12 month low of $47.31 and a 12 month high of $94.99. The stock’s 50 day moving average is $51.53 and its two-hundred day moving average is $62.13. The company has a current ratio of 1.72, a quick ratio of 1.04 and a debt-to-equity ratio of 1.04.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. CenterBook Partners LP acquired a new position in shares of Haemonetics during the 3rd quarter worth approximately $324,000. May Hill Capital LLC lifted its position in Haemonetics by 24.7% during the third quarter. May Hill Capital LLC now owns 22,348 shares of the medical instruments supplier’s stock worth $1,089,000 after buying an additional 4,431 shares in the last quarter. GSA Capital Partners LLP acquired a new position in Haemonetics during the third quarter worth $618,000. State of New Jersey Common Pension Fund D grew its holdings in Haemonetics by 38.4% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 39,405 shares of the medical instruments supplier’s stock valued at $1,921,000 after buying an additional 10,937 shares in the last quarter. Finally, ABN Amro Investment Solutions acquired a new stake in shares of Haemonetics in the 3rd quarter worth $186,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.